Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

Prometic announces successful treatment of a plasminogen-deficient patient under an expanded access (compassionate use) protocol in the USA

PR Newswire May 3, 2016

INVESCO INVESTMENT TRUSTS - Portfolio Disclosure

PR Newswire UK Disclosure May 3, 2016

ProMetic's PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial

Canada NewsWire April 26, 2016

ProMetic confirms PBI-4050's Anti-Fibrotic Effect in Nash Model and on Human Hepatic Stellate Cells

Canada NewsWire April 14, 2016

ProMetic reports its 2015 fourth quarter and year end highlights and financial results

Canada NewsWire March 30, 2016

ProMetic confirms PBI-4050's positive effects on novel biomarkers in patients suffering from metabolic syndrome and Type 2 diabetes

Canada NewsWire March 22, 2016

ProMetic to report its fourth quarter and year end 2015 financial results and hold conference call / webcast

Canada NewsWire March 21, 2016

ProMetic announces the addition of scleroderma to PBI-4050's targeted indications

Canada NewsWire March 15, 2016

ProMetic secures $30 million follow-on financing from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.

Canada NewsWire March 1, 2016

OTC Markets Group Announces the 2016 OTCQX Best 50

Press Releases February 17, 2016

ProMetic Provides 2016 Milestones Outlook at BIO-CEO Conference in New York

Canada NewsWire February 9, 2016

Prometic Provides Revenue Guidance Update

Canada NewsWire December 17, 2015

Prometic's PBI-4050 To Target Cystic Fibrosis As Its Next Orphan Indication

Canada NewsWire December 14, 2015

ProMetic to disclose new PBI-4050 orphan indication and hold conference call / webcast

Canada NewsWire December 11, 2015

ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case

Canada NewsWire December 7, 2015

ProMetic renews long-term supply agreement with GlaxoSmithKline LLC

Canada NewsWire December 4, 2015

ProMetic confirms PBI-4050's efficacy in patients suffering from type 2 diabetes and metabolic syndrome

Canada NewsWire December 1, 2015

ProMetic to present at the Piper Jaffray 27th Annual Healthcare Conference in New York on Tuesday December 1, 2015

Canada NewsWire November 24, 2015

ProMetic enters into strategic agreements with ProThera Biologics to develop plasma-derived Inter-alpha Inhibitor Proteins ("IAIP") for orphan diseases

Canada NewsWire November 19, 2015

ProMetic reports its third quarter 2015 highlights and financial results

Canada NewsWire November 12, 2015